免疫检查点抑制剂诱导的多发性肌痛风湿症
David F L Liew1, Sarah L Mackie2, Alice Tison3
1Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia.
Rheumatic diseases clinics of North America
|April 26, 2024
概括
多肌痛风湿免疫相关不良事件 (ICI-PMRs) 与经典的PMR不同,尽管区分它们会带来挑战. ICI-PMR可以作为理解诱导多发性肌痛性风湿症的模型.
科学领域:
- 风湿病学和免疫学
- 在瘤学瘤学.
- 临床医学 临床医学
背景情况:
- 多肌痛性风湿性免疫相关不良事件 (ICI-PMRs) 是一种新发现的疾病.
- ICI-PMR与经典的多发性肌痛性风湿症 (PMR) 有着相同的临床,实验室和成像特征.
- 关于ICI-PMR与经典PMR和其他条件的区别,仍有很多问题没有得到答案.
研究的目的:
- 要突出ICI-PMR的独特性质,尽管与经典PMR有相似之处.
- 解决区分ICI-PMR与经典PMR和模仿者的挑战.
- 探索ICI-PMR作为诱导PMR的一个模型的潜力.
主要方法:
- 临床,实验室和成像数据的比较分析.
- 审查关于ICI-PMR和经典PMR的现有文献.
- 讨论治疗策略和影响.
主要成果:
- ICI-PMR是一个与经典PMR相似的新型实体.
- 区分ICI-PMR与经典PMR和其他疾病仍然是复杂的.
- 目前ICI-PMR的治疗是基于经典的PMR指导方针,并考虑免疫治疗.
结论:
- ICI-PMR代表了一个独特的条件,需要仔细区分.
- 对ICI-PMR的进一步研究可能会为经典的PMR提供洞察力.
- ICI-PMR可以作为一种有价值的模型,以了解诱导的PMR及其治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K


